Expert Consultations: Real-World Answers

Dopamine and Depression: Clinical Considerations – Interview

Published on April 1, 2021 Expired on April 1, 2023

Guest

Wegdan Rashad

To unlock this audio you need to become a Silver, Gold, Silver extended, Gold extended, Gold – fr, Gold extended – fr, Silver – fr or Silver extended – fr Member.

Check Our CME Program

Downloads for Offline Access

Download Audio File (MP3)

Interview Highlights

Anhedonia and anergia are core symptoms of biological depression, which may be underrecognized in DSM-5.
Dopamine plays a key role in the neurochemical basis of melancholic depression.
MAOIs, which enhance dopaminergic neurotransmission, may be useful in the treatment of melancholic biological depression and Parkinson's disease.
The possibility of pharmacodynamic interactions, which may lead to serotonin toxicity or tyramine crisis, must be taken into consideration when prescribing MAOIs.

Text Version

This edition of Psychopharmacology Institute’s Expert Consultations features Dr. Ken Gillman, who is a psychiatrist, an MAOI groups convener, and the establisher of Psychotropical , a website focusing on MAOIs. In this interview, we will discuss an article that Dr. Gillman published on his website, entitled “ Dopamine and Depression ”. It addressed reflections on how we think

Unlock this Expert Consultation and earn 0.50 CMEs
Become a Silver, Gold, Silver extended, Gold extended, Gold – fr, Gold extended – fr, Silver – fr or Silver extended – fr Member.

Get Instant Access

Already have an account? Sign in

Learning Objectives:

After completing this activity, the learner will be able to:

Recognize the role of dopaminergic deficits in precipitating core symptoms of depression, such as anhedonia and anergia.
Discuss the clinical utility of monoamine oxidase inhibitors for the treatment of patients manifesting with severe melancholic or biological depression and Parkinson's disease.
Identify possible detrimental effects of dopaminergic antagonists, such as atypical antipsychotics, when used as adjunctive therapy for patients manifesting with core symptoms of depression.

Original Release Date: 04/01/2021

Review and Re-release Date: 03/01/2023

Expiration Date: 04/01/2023

Relevant Financial Disclosures:

The following planners, faculty, and reviewers have the following relevant financial relationships with commercial interests to disclose:

Dr. Gillman has disclosed the following relationships:

Neurawell Therapeutics -- regarding a reformulation of tranylcypromine.: Consulting

All of the relevant financial relationships listed for these individuals have been mitigated.

Contact Information: For questions regarding the content or access to this activity, contact us at support@ml-prod.psychopharmacologyinstitute.com

Instructions for Participation and Credit:

Participants must complete the activity online during the valid credit period that is noted above.

Follow these steps to earn CME credit:

View the required educational content provided on this course page.
Answer the quiz for promoting retention of knowledge.
Complete the Post Activity Evaluation for providing the necessary feedback for continuing accreditation purposes and for the development of future activities. NOTE: Completing the Post Activity Evaluation after the quiz is required to receive the earned credit.
Download your certificate.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Medical Academy LLC and the Psychopharmacology Institute. Medical Academy is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

Medical Academy designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Ken Gillman, M.D.